Reports of Biochemistry
and Molecular Biology
Thu, Nov 21, 2024
[Archive]
Volume 13, Issue 1 (Vol.13 No.1 Apr 2024)
rbmb.net 2024, 13(1): 137-143 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Samara T D, Wartono M, Kosasih A, Alvina A. Association of Body Mass Index with Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1, and Interleukin-6 Based on Blood Pressure. rbmb.net 2024; 13 (1) :137-143
URL: http://rbmb.net/article-1-1357-en.html
URL: http://rbmb.net/article-1-1357-en.html
Department of Anatomy, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia.
Abstract: (166 Views)
Background: high body mass index (BMI) is known to be associated with high blood pressure. Levels of matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), and interleukin-6 (IL-6) are also increased in hypertensive patients. The aim of this study was to determine the correlation of BMI with MMP-9, TIMP-1, and IL-6 based on blood pressure.
Methods: The study design was cross-sectional with subjects aged >= 36 years, male and female and divided into 3 groups: group with normal blood pressure (NBP), group with controlled hypertension (CHT), and group with uncontrolled hypertension (UcHT). Height, weight, and blood pressure were measured, as well as serum levels of MMP-9, TIMP-1 and IL-6 using the ELISA method. The correlation was considered significant at p-value of < 0.05.
Result: The BMI in group UcHT was higher than in the other groups. THERE was a positive correlation between BMI and MMP-9; BMI and TIMP-1; and BMI and IL-6 (r=0.480, p=0.007; r=0.620; p=0.000; r=374, p=0.042 respectively) in group UcHT.
Conclusions: An increase in BMI is accompanied by an increase in levels of MMP-9, TIMP-1, and IL-6 in group UcHT, signifying that it is necessary to control BMI to maintain stable levels of MMP-9, TIMP-1, and IL-6, thereby keeping blood pressure under control.
Methods: The study design was cross-sectional with subjects aged >= 36 years, male and female and divided into 3 groups: group with normal blood pressure (NBP), group with controlled hypertension (CHT), and group with uncontrolled hypertension (UcHT). Height, weight, and blood pressure were measured, as well as serum levels of MMP-9, TIMP-1 and IL-6 using the ELISA method. The correlation was considered significant at p-value of < 0.05.
Result: The BMI in group UcHT was higher than in the other groups. THERE was a positive correlation between BMI and MMP-9; BMI and TIMP-1; and BMI and IL-6 (r=0.480, p=0.007; r=0.620; p=0.000; r=374, p=0.042 respectively) in group UcHT.
Conclusions: An increase in BMI is accompanied by an increase in levels of MMP-9, TIMP-1, and IL-6 in group UcHT, signifying that it is necessary to control BMI to maintain stable levels of MMP-9, TIMP-1, and IL-6, thereby keeping blood pressure under control.
Keywords: Body mass index (BMI), Blood pressure, Interleukin-6 (IL-6), Matrix metalloproteinase-9 (MMP-9), Tissue inhibitor of metalloproteinase-1 (TIMP-1)
Type of Article: Original Article |
Subject:
Molecular Biology
Received: 2024/03/8 | Accepted: 2024/06/9 | Published: 2024/10/22
Received: 2024/03/8 | Accepted: 2024/06/9 | Published: 2024/10/22
References
1. World Health Organization. Hypertension. https://www.who.int.
2. Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75(2):285-92. [DOI:10.1161/HYPERTENSIONAHA.119.14240] [PMID] []
3. Gelzo M, Cacciapuoti S, Pinchera B, De Rosa A, Cernera G, Scialò F, et al. Matrix metalloproteinases (MMP) 3 and 9 as biomarkers of severity in COVID-19 patients. Sci Rep. 2022;12(1):1212. [DOI:10.1038/s41598-021-04677-8] [PMID] []
4. Singh S, Shankar R, Singh GP. Prevalence and Associated Risk Factors of Hypertension: A Cross-Sectional Study in Urban Varanasi. Int J Hypertens. 2017;2017:5491838. [DOI:10.1155/2017/5491838] [PMID] []
5. Midha T, Krishna V, Shukla R, Katiyar P, Kaur S, Martolia DS, et al. Correlation between hypertension and hyperglycemia among young adults in India. World J Clin Cases. 2015;3(2):171-9. [DOI:10.12998/wjcc.v3.i2.171] [PMID] []
6. Ritter AM, de Faria AP, Barbaro N, Sabbatini AR, Corrêa NB, Brunelli V, et al. Crosstalk between obesity and MMP-9 in cardiac remodelling -a cross-sectional study in apparent treatment-resistant hypertension. Blood Press. 2017;26(2):122-129. [DOI:10.1080/08037051.2016.1249336] [PMID]
7. Boumiza S, Chahed K, Tabka Z, Jacob MP, Norel X, Ozen G. MMPs and TIMPs levels are correlated with anthropometric parameters, blood pressure, and endothelial function in obesity. Sci Rep. 2021;11(1):20052. [DOI:10.1038/s41598-021-99577-2] [PMID] []
8. Ma Y, de Castro Brás LE, Toba H, Iyer RP, Hall ME, Winniford MD, et al. Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflügers Archiv-European Journal of Physiology. 2014;466(6):1113-27. [DOI:10.1007/s00424-014-1463-9] [PMID] []
9. Xiao W, Wang L, Howard J, Kolhe R, Rojiani AM, Rojiani MV. TIMP-1-Mediated Chemoresistance via Induction of IL-6 in NSCLC. Cancers. 2019;11(8):1184. [DOI:10.3390/cancers11081184] [PMID] []
10. Minafra AR, Chadt A, Rafii P, Al-Hasani H, Behnke K, Scheller J. Interleukin 6 receptor is not directly involved in regulation of body weight in diet-induced obesity with and without physical exercise. Front Endocrinol. 2022;13:1028808. [DOI:10.3389/fendo.2022.1028808] [PMID] []
11. Sushith S, Krishnamurthy HN, Reshma S, Janice D, Madan G, Ashok KJ, et al. Serum Ischemia-Modified Albumin, Fibrinogen, High Sensitivity C- Reactive Proteins in Type-2 Diabetes Mellitus without Hypertension and Diabetes Mellitus with Hypertension: A Case-Control Study. Rep Biochem Mol Biol. 2020;9(2):241-249. [DOI:10.29252/rbmb.9.2.241] [PMID] []
12. Landi F, Calvani R, Picca A, Tosato M, Martone AM, Ortolani E, et al. Body mass index is strongly associated with hypertension: Results from the longevity check-up 7+ study. Nutrients. 2018;10(12):1976. [DOI:10.3390/nu10121976] [PMID] []
13. Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res. 2007;30(10):959-63. [DOI:10.1291/hypres.30.959] [PMID]
14. Lindsey ML, Yabluchanskiy A, Ma Y. Tissue Inhibitor of Metalloproteinase-1: Actions beyond Matrix Metalloproteinase Inhibition. Cardiology. 2015;132(3):147-50. [DOI:10.1159/000433419] [PMID] []
15. Ishikawa J, Hirose H, Ishikawa S. Tissue Inhibitor of Matrix Metalloproteinase 1 Increases With Ageing and Can Be Associated With Stroke - Nested Case-Control Study. Circ Rep. 2019;1(11):502-507. [DOI:10.1253/circrep.CR-19-0084] [PMID] []
16. Hashmat S, Rudemiller N, Lund H, Abais-Battad JM, Van Why S, Mattson DL. Interleukin-6 inhibition attenuates hypertension and associated renal damage in Dahl salt-sensitive rats. Am J Physiol Renal Physiol. 2016;311(3):F555-61. [DOI:10.1152/ajprenal.00594.2015] [PMID] []
17. Bisogni V, Cerasari A, Pucci G, Vaudo G. Matrix Metalloproteinases and Hypertension-Mediated Organ Damage: Current Insights. Integr Blood Press Control. 2020;13:157-169. [DOI:10.2147/IBPC.S223341] [PMID] []
18. Prado AF, Batista RIM, Tanus-Santos JE, Gerlach RF. Matrix Metalloproteinases and Arterial Hypertension: Role of Oxidative Stress and Nitric Oxide in Vascular Functional and Structural Alterations. Biomolecules. 2021;11(4):585. [DOI:10.3390/biom11040585] [PMID] []
19. Zhu JJ, Zhao Q, Qu HJ, Li XM, Chen QJ, Liu F, et al. Usefulness of plasma matrix metalloproteinase-9 levels in prediction of in-hospital mortality in patients who received emergent percutaneous coronary artery intervention following myocardial infarction. Oncotarget. 2017;8(62):105809-105818. [DOI:10.18632/oncotarget.22401] [PMID] []
20. Głowińska-Olszewska B, Urban M. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism. 2007;56(6):799-805. [DOI:10.1016/j.metabol.2007.01.011] [PMID]
21. Kostov K, Blazhev A. Changes in Serum Levels of Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Essential Hypertension. Bioengineering. 2022;9(3):119. [DOI:10.3390/bioengineering9030119] [PMID] []
22. Krüttgen A, Rose-John S. Interleukin-6 in sepsis and capillary leakage syndrome. J Interferon Cytokine Res. 2012;32(2):60-5. [DOI:10.1089/jir.2011.0062] [PMID]
23. Tanase DM, Gosav EM, Radu S, Ouatu A, Rezus C, Ciocoiu M, et al. Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker? Int J Hypertens. 2019;2019:3159283. [DOI:10.1155/2019/3159283] [PMID] []
24. Fuster JJ, Ouchi N, Gokce N, Walsh K. Obesity-Induced Changes in Adipose Tissue Microenvironment and Their Impact on Cardiovascular Disease. Circ Res. 2016;118(11):1786-807. [DOI:10.1161/CIRCRESAHA.115.306885] [PMID] []
25. Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front Cardiovasc Med. 2020;7:22. [DOI:10.3389/fcvm.2020.00022] [PMID] []
26. Oluboyo A, Okoro C, Ekpo V, Oluboyo B. Assessment of interleukins 1 and 6 in hypertensive subjects. Int J Biol Chem Sci. 2019;13(6):2513-20. [DOI:10.4314/ijbcs.v13i6.7]
27. Tadi S. Interleukin-6, uric acid, and electrolytes for the detection of endothelial dysfunction in pre-hypertensive and hypertensive patients. Int J Med Sci Public Health. 2019; 8(3): 248-254. [DOI:10.5455/ijmsph.2019.0823026012019001]
28. Mohammadi M, Gozashti MH, Aghadavood M, Mehdizadeh MR, Hayatbakhsh MM. Clinical Significance of Serum IL-6 and TNF-α Levels in Patients with Metabolic Syndrome. Rep Biochem Mol Biol. 2017;6(1):74-79.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
